List of Excipients in Branded Drug GLIPIZIDE ER

Generic Drugs Containing GLIPIZIDE ER

Company	Ingredient	NDC	Excipient
DirectRX	glipizide er	61919-725	ACETYLTRIBUTYL CITRATE
DirectRX	glipizide er	61919-725	AMMONIA
DirectRX	glipizide er	61919-725	BUTYL ALCOHOL
DirectRX	glipizide er	61919-725	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in GLIPIZIDE ER?

# Of NDCs	Excipient
1	ACETYLTRIBUTYL CITRATE
1	AMMONIA
1	BUTYL ALCOHOL
1	FERROSOFERRIC OXIDE

Glipizide ER Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Glipizide extended-release, marketed in the United States as Glucotrol XL and available from multiple generic manufacturers, is a mature oral antidiabetic product with limited brand-price opportunity but viable generic, contract-manufacturing, and emerging-market potential. The main technical barrier is controlled drug release rather than the glipizide molecule itself. A successful product must reproduce the reference product’s 24-hour release profile, control food and alcohol effects, maintain tablet integrity, and demonstrate bioequivalence under fasting and fed conditions.

What is glipizide ER and how is it regulated?

Glipizide ER is an oral extended-release formulation of glipizide, a second-generation sulfonylurea used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The U.S. reference product contains 2.5 mg, 5 mg, and 10 mg strengths and is administered once daily with breakfast or the first main meal of the day [1].

Glipizide ER is regulated as a small-molecule drug. It is not a biologic and does not create biosimilar competition. Generic manufacturers generally use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Attribute	Glipizide ER
Active ingredient	Glipizide
Therapeutic class	Sulfonylurea
Dosage form	Extended-release tablet
Typical strengths	2.5 mg, 5 mg, 10 mg
Administration	Once daily
U.S. reference product	Glucotrol XL
Regulatory pathway	ANDA for generics
Biosimilar exposure	None
Primary technical issue	Reproducing controlled-release performance
Primary commercial issue	Low price and mature generic competition

The reference product uses a controlled-release tablet architecture associated with an osmotic delivery system. The tablet releases drug through a controlled orifice as water enters the dosage form. An insoluble tablet shell or membrane may pass through the gastrointestinal tract and appear in the stool, a feature described in the prescribing information [1].

What excipients are used in glipizide ER tablets?

The reference formulation uses excipients that support osmotic control, membrane integrity, lubrication, and tablet processing. Public labeling identifies excipient classes including polyethylene oxide, hypromellose, magnesium stearate, sodium chloride, cellulose acetate, and coating components [1].

Functional role of the main excipients

Excipient or excipient class	Primary role in glipizide ER
Polyethylene oxide	Swelling polymer, hydrogel or osmotic push-layer function
Hypromellose	Matrix-forming polymer, viscosity control, release modulation
Sodium chloride	Osmogen that increases osmotic pressure
Cellulose acetate	Semipermeable membrane-forming polymer
Magnesium stearate	Lubricant
Film-coating materials	Identification, protection, and appearance
Colorants	Strength differentiation and product identification

The exact quantitative composition, processing parameters, membrane weight gain, orifice dimensions, and core geometry are not fully disclosed in the commercial label. These parameters can have a greater effect on release than nominal excipient identity.

For an ANDA applicant, matching the reference product’s release mechanism may require a Q1/Q2-equivalent formulation, where Q1 means the same inactive ingredients and Q2 means comparable quantitative composition. A different formulation may still be approvable, but it faces a more demanding demonstration that the drug-product performance is equivalent.

What excipient strategy is appropriate for a glipizide ER generic?

The strongest development strategy is to select the release platform before optimizing tablet composition. Three approaches are commercially relevant.

Osmotic tablet strategy

An osmotic tablet is the closest technical route to the reference product. The formulation generally includes a drug-containing core, an osmotic or swelling component, a semipermeable membrane, and a laser-drilled or mechanically formed delivery orifice.

Key development variables include:

• Polyethylene oxide molecular weight and concentration
• Sodium chloride loading
• Core hardness and porosity
• Membrane polymer grade
• Membrane thickness and weight gain
• Orifice diameter and placement
• Tablet coating uniformity
• Residual solvent and moisture
• Manufacturing compression force

The advantage is a predictable, near-zero-order release profile with reduced dependence on gastrointestinal pH. The disadvantages are higher equipment costs, specialized coating capability, laser drilling or equivalent processing, and greater scale-up complexity.

Hydrophilic matrix strategy

A hydrophilic matrix using hypromellose or polyethylene oxide can provide a lower-cost alternative. Drug release occurs through polymer hydration, gel formation, diffusion, and matrix erosion.

This approach can reduce manufacturing complexity, but it may be more sensitive to:

• Food intake
• Gastric residence time
• Agitation intensity
• Polymer hydration
• Tablet size and hardness
• Alcohol exposure
• GI pH and transit conditions

A matrix formulation must be tested extensively for dose dumping under alcohol-containing media. A formulation that appears equivalent in standard dissolution testing may fail under stress conditions.

Multiparticulate or coated-particle strategy

Drug-layered pellets, coated granules, or multiparticulates can provide flexible release control and may support alternative dosage forms. They are technically attractive for patients who have difficulty swallowing tablets, but they add manufacturing steps and may create new risks involving coating uniformity, segregation, dose distribution, and capsule or sachet filling.

This platform has greater commercial value if combined with a sprinkle formulation, orally disintegrating presentation, or flexible-dose product. Such products would require specific regulatory and clinical justification because the reference product is an extended-release tablet.

What dissolution and bioequivalence requirements apply?

Glipizide ER development requires a discriminatory dissolution method that distinguishes meaningful formulation changes. A single-point dissolution specification is unlikely to be sufficient for development control.

A practical dissolution program should evaluate:

1. Multiple time points covering the full release period.
2. Several pH conditions, including acidic and near-neutral media.
3. Agitation-rate sensitivity.
4. Media with and without surfactant where justified.
5. Alcohol challenge conditions.
6. Release performance after storage.
7. Tablet integrity and residual shell behavior.
8. Comparative profiles against the reference product.

FDA modified-release guidance emphasizes the importance of fed and fasting studies, dose proportionality where relevant, and assessment of alcohol-induced dose dumping [2]. The applicant should expect formulation changes to affect both in vitro release and in vivo exposure.

The critical pharmacokinetic endpoints are generally area under the curve and maximum concentration. The release profile must avoid an excessive early exposure peak while maintaining adequate 24-hour exposure.

What commercial opportunities exist for glipizide ER?

The largest opportunity is cost-efficient generic supply rather than premium pricing. Glipizide ER is a mature product with established physician familiarity and low switching barriers.

Generic product opportunities

Potential generic strategies include:

• A low-cost 2.5 mg, 5 mg, and 10 mg portfolio
• Regional supply in markets with limited modified-release competition
• Authorized-generic manufacturing
• Contract manufacturing for branded or regional pharmaceutical companies
• Dual sourcing for distributors and public tenders
• Supply agreements with institutional pharmacies
• Line extensions using differentiated packaging or adherence support

The 2.5 mg strength may have strategic value because it supports dose initiation and titration. The 5 mg and 10 mg strengths are likely to carry greater unit volume but face stronger price competition.

Emerging-market opportunity

Glipizide remains relevant in markets where newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors are less accessible because of price or reimbursement restrictions. Extended release offers a once-daily dosing proposition, but local demand depends on:

• Diabetes prevalence
• Availability of glucose monitoring
• Sulfonylurea prescribing patterns
• National essential-medicine policies
• Local bioequivalence requirements
• Tender pricing
• Distribution reliability

A manufacturer may obtain better returns from regulatory registration and local supply in selected markets than from competing directly in the U.S. retail generic market.

Contract manufacturing and licensing

The most practical licensing assets are likely to be:

• Validated osmotic-tablet technology
• Modified-release manufacturing know-how
• Laser-drilling or membrane-coating capability
• Regional marketing rights
• Established ANDA or equivalent regulatory dossiers
• Alternative dosage forms
• Stable, low-cost supply of polyethylene oxide, hypromellose, and cellulose acetate

A formulation patent alone may have limited commercial value because the original reference-product patents are historical and the product is already genericized. Manufacturing know-how, regulatory approvals, and supply reliability may be more valuable than broad composition claims.

What patents protect glipizide ER?

Glipizide ER historically relied on patents covering controlled-release oral dosage forms and osmotic delivery technologies. Those original U.S. patent rights have expired, and glipizide ER is generally treated as a mature generic product.

The U.S. Orange Book remains the authoritative source for current listed patents and exclusivity information [3]. A commercial diligence review should distinguish among:

• Expired formulation patents
• Expired drug-delivery platform patents
• Any later-listed method-of-use patents
• Pediatric exclusivity
• Patent certifications submitted by ANDA applicants
• Litigation tied to listed patents
• Patent rights outside the United States

There is no biosimilar patent risk because glipizide is a synthetic small molecule. Patent risk is concentrated in formulation design, manufacturing processes, and any jurisdiction where older rights have different expiration rules.

When did glipizide ER lose exclusivity?

U.S. market exclusivity for the original glipizide ER product ended years ago, and generic competition is established. The product does not present the conventional “patent cliff” profile associated with recently approved drugs.

The relevant commercial question is therefore not when the brand loses exclusivity, but whether a new entrant can achieve:

• Approval without a lengthy patent dispute
• Acceptable bioequivalence
• Consistent modified-release manufacturing
• Competitive cost of goods
• Sufficient volume to justify specialized equipment
• Reliable API and excipient supply

Any active Orange Book listing, litigation, or settlement should be checked against the current FDA database before a launch decision. Historical patent expiration dates should not be used as a substitute for a live Orange Book review.

Are there Paragraph IV challenges or settlements involving glipizide ER?

Paragraph IV litigation was relevant during the original genericization of Glucotrol XL. The commercial importance of those historical disputes has declined because the main product patents expired and multiple generic products entered the market.

For a new applicant, the current legal assessment should focus on:

• Whether the reference product has any active Orange Book-listed patent
• Whether the ANDA applicant can make a Paragraph IV certification
• Whether a 30-month stay could be triggered
• Whether a settlement restricts launch timing
• Whether non-listed process or manufacturing patents create separate risk

A generic applicant should not assume that the absence of a current patent dispute eliminates all IP risk. Manufacturing patents, trade secrets, and supplier agreements can still affect launch execution, although they generally present less direct risk than an active Orange Book formulation patent.

How strong is the glipizide ER patent estate?

The current patent estate is weak from a product-exclusivity perspective but potentially important from a formulation-engineering perspective.

Patent-risk category	Current commercial significance
Original glipizide ER formulation patents	Low if expired
Osmotic delivery platform patents	Low for historical claims; relevant only if later claims remain active
New matrix formulations	Potentially relevant if technically differentiated
Manufacturing process patents	Moderate in specialized tablet production
Method-of-use patents	Generally limited for a mature sulfonylurea
Trade secrets	Moderate, especially for coating and release control
Foreign patent rights	Market-specific
Biosimilar patents	Not applicable

A new entrant should avoid relying on a simple “expired patent” conclusion. Freedom-to-operate should cover the proposed polymer grades, membrane composition, processing sequence, drilling method, and any alternative dosage form.

What manufacturing and supply barriers affect glipizide ER?

The principal barrier is specialized modified-release manufacturing. An immediate-release glipizide product can be made with conventional granulation and compression equipment. An ER product may require controlled coating, membrane application, precision orifice formation, and tight in-process testing.

Supply-chain risks include:

• Variability in polyethylene oxide molecular weight
• Hypromellose viscosity variation
• Cellulose acetate substitution
• Sodium chloride particle-size differences
• Coating-polymer supply interruptions
• Lubricant overmixing
• Moisture-driven release changes
• API particle-size variation

Excipient suppliers should be qualified not only by compendial compliance but also by functional performance. A different grade of the same compendial excipient can change hydration, swelling, membrane permeability, or dissolution.

How does glipizide ER compare with newer diabetes drugs?

Glipizide ER has lower acquisition cost and long clinical familiarity. Newer products such as metformin combinations, SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists have stronger differentiation in cardiovascular, renal, weight, or hypoglycemia-related outcomes, depending on the product.

Factor	Glipizide ER	Newer branded diabetes drugs
Cost	Low	Often substantially higher
Dosing	Once daily	Product-dependent
Patent opportunity	Limited	Often substantial
Weight effect	May increase weight	Some products reduce weight
Hypoglycemia risk	Established risk	Class-dependent
Manufacturing complexity	Moderate to high for ER	Product-dependent
Commercial growth	Mature	Often stronger before patent expiry

Glipizide ER’s commercial role is strongest where affordability, availability, and oral once-daily administration outweigh the clinical advantages of newer therapies.

Key Takeaways

• Glipizide ER is a mature, genericized small-molecule product with no biosimilar exposure.
• The main technical challenge is reproducing controlled release over approximately 24 hours.
• Osmotic technology most closely aligns with the reference-product performance but requires specialized equipment and process control.
• Hydrophilic matrices reduce manufacturing cost but can create greater food, agitation, and alcohol sensitivity.
• The highest-value excipient controls involve polyethylene oxide, hypromellose, sodium chloride, cellulose acetate, and lubricant levels.
• Commercial opportunity is concentrated in low-cost generic supply, emerging markets, contract manufacturing, and regional licensing.
• Original U.S. exclusivity has ended; current Orange Book listings and jurisdiction-specific patents must be checked before launch.
• Manufacturing know-how and validated dissolution performance may be more valuable than expired formulation patents.
• The 2.5 mg, 5 mg, and 10 mg strengths should be assessed separately for demand, pricing, and production economics.

FAQs

Can glipizide ER be reformulated with different excipients?

Yes, but a different excipient system must still demonstrate equivalent release and pharmacokinetic performance. The farther the formulation departs from the reference product, the greater the development and regulatory risk.

Is polyethylene oxide essential for glipizide extended release?

No. Polyethylene oxide is a strong candidate for osmotic or swelling control, but hypromellose and other polymers can support alternative release mechanisms. The selected polymer must deliver reproducible release under physiological and stress conditions.

Does glipizide ER require alcohol dose-dumping studies?

Yes. Modified-release products should be evaluated under alcohol-challenge conditions because alcohol can accelerate polymer hydration, membrane permeability, or drug release.

Is a glipizide ER sprinkle capsule commercially attractive?

Potentially, but the opportunity is niche. A sprinkle product could address swallowing difficulty, while adding development work for dose uniformity, stability, labeling, and administration instructions.

What is the most defensible commercial advantage for a new glipizide ER entrant?

The strongest advantages are low cost of goods, dependable supply, validated release performance, regional registration, and differentiated manufacturing capability. Patent exclusivity is unlikely to provide the principal advantage in the United States.

References

1. Pfizer Inc. (2023). Glucotrol XL (glipizide extended release tablets) prescribing information. U.S. Food and Drug Administration, DailyMed.

2. U.S. Food and Drug Administration. (1997). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.